Aspyra Enters Into Reseller Agreement with BioInfoComm.

CALABASAS, Calif. -- Aspyra, Inc. (AMEX:APY) announced today that it has entered into a reseller agreement with BioInfoComm Pte Ltd (BIC) allowing BIC to resell Aspyra's CyberLABPP([R]PP) Laboratory Information System (LIS) throughout Singapore, Malaysia, India, Hong Kong, Brunei and Indonesia, with future plans to expand into Thailand, China, Korea and Japan. BioInfoComm is a company specializing primarily in Healthcare innovation technologies and consultancy services, with offices located in Singapore and Malaysia.

"Aspyra's LIS solution is designed to enhance the clinical laboratory workflow, boost efficiency and improve patient safety within the hospital, multi-specialty clinic and reference laboratory environments," stated Aspyra President and Chief Executive Officer Steven M. Besbeck. "With successful LIS installations already located in Malaysia and Southeast Asia, Aspyra understands the audience BIC focuses on and can provide the right solution for their customers. In addition, this agreement further positions Aspyra toward its goals of expanding business globally."

"Many of the hospital laboratories have either outgrown their existing LIS due to increased sample volume, or simply are in need of electronic record keeping and other features available in today's LIS using the latest technologies," states Lee Kok Keong, founder and managing director of BIC. Mr. Lee continues, "Aspyra's LIS solution provides a cost-effective solution that enables these laboratories to improve their workflow and gain efficiency in areas such as order placement and result processing."

The initial 2-year reseller agreement became effective October 16, 2006.

Aspyra's CyberLABPP([R]PP) LIS system is a scalable, feature-rich, and proven LIS solution for the hospital, clinic, and reference laboratory settings. CyberLABPP([R]PP) features decision support tools with auto-verification, automated clinical reporting and multisite management.

About BioInfoComm Pte Ltd

BioInfoComm (BIC) focuses and specializes primarily in Healthcare innovation technologies and consultancy services. BICs mission is to promote healthy systems and quality of work environment in this region by facilitating and advising clients to excel through IT innovation, work process enhancements and value-added services. To promote quality, BIC provides coordination of CAP-LAP accreditation programs to facilitate their laboratory partners to excel. The unique structure of the company enables them to facilitate, advise and champion their clients' cause from both the user and vendor aspect. For more information on BioInfoComm, visit www.bioinfocomm.com.

About Aspyra

Aspyra is a global provider of Health Care Information Technology (HCIT) solutions and services to the healthcare industry. The Company specializes in Clinical Information Systems (CIS), Picture Archive Communication Systems (PACS) and Clinical Image Management Systems (CIMS) for hospitals, multi-specialty clinics, clinical laboratories, imaging departments and centers, orthopedic environments and pharmacies. Aspyra's highly scalable systems can be installed standalone or integrated to provide a single-vendor, enterprise-wide solution. For more information on Aspyra, its products and services, visit www.aspyra.com.

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for Aspyra's markets and the demand for its products. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. Factors that could cause Aspyra's actual results to differ materially from these forward-looking statements include among others: whether the combined company will realize the potential benefits of the merger; the competitive environment; unexpected technical and marketing difficulties inherent in major product development efforts; the potential need for changes in our long-term strategy in response to future developments; future advances in clinical information technology and procedures, as well as potential changes in government regulations and healthcare policies; and rapid technological change in the microelectronics and software industries. The Company refers interested persons to its most recent Annual Report on Form 10-KSB and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements.